Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Danish (OMX) Healthcare Sector Analysis

UpdatedApr 06, 2026
DataAggregated Company Financials
Companies20
  • 7D3.7%
  • 3M-27.8%
  • 1Y-37.8%
  • YTD-25.0%

Over the last 7 days, the Healthcare industry has risen 3.7%, driven by gains from Novo Nordisk of 2.5%. However, the industry is down 38% over the past year. Earnings are forecast to grow by 5.2% annually.

Sector Valuation and Performance

Has the Danish Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Mon, 06 Apr 2026DKK 1.5tDKK 447.8bDKK 130.1b17.4x11.3x3.3x
Wed, 04 Mar 2026DKK 1.5tDKK 448.2bDKK 131.1b17.5x11.1x3.2x
Fri, 30 Jan 2026DKK 2.1tDKK 453.2bDKK 136.7b17.5x15.6x4.7x
Sun, 28 Dec 2025DKK 2.0tDKK 453.7bDKK 136.8b17.1x14.4x4.3x
Tue, 25 Nov 2025DKK 1.8tDKK 454.3bDKK 137.1b17.4x13x3.9x
Thu, 23 Oct 2025DKK 2.0tDKK 447.8bDKK 141.8b18.9x14.4x4.5x
Sat, 20 Sep 2025DKK 2.2tDKK 447.3bDKK 141.7b19x15.7x5x
Mon, 18 Aug 2025DKK 1.9tDKK 444.4bDKK 140.2b28.1x13.6x4.3x
Wed, 16 Jul 2025DKK 2.4tDKK 423.3bDKK 124.5b29.9x19.1x5.6x
Fri, 13 Jun 2025DKK 2.8tDKK 423.4bDKK 124.6b31.2x22.4x6.6x
Sun, 11 May 2025DKK 2.4tDKK 423.4bDKK 124.9b22.6x19.4x5.7x
Tue, 08 Apr 2025DKK 2.4tDKK 409.5bDKK 121.3b21.9x19.5x5.8x
Thu, 06 Mar 2025DKK 3.3tDKK 409.9bDKK 121.4b27.7x27.4x8.1x
Sat, 01 Feb 2025DKK 3.3tDKK 387.7bDKK 111.4b28.8x29.2x8.4x
Mon, 30 Dec 2024DKK 3.4tDKK 387.4bDKK 111.3b29.9x30.1x8.7x
Wed, 27 Nov 2024DKK 3.9tDKK 387.4bDKK 111.3b31x35.2x10.1x
Fri, 25 Oct 2024DKK 4.1tDKK 372.2bDKK 107.2b33.7x38x10.9x
Sun, 22 Sep 2024DKK 4.4tDKK 371.9bDKK 107.1b37.4x40.8x11.8x
Tue, 20 Aug 2024DKK 4.7tDKK 370.7bDKK 107.0b37.4x43.8x12.6x
Thu, 18 Jul 2024DKK 4.7tDKK 355.2bDKK 106.2b35.3x43.8x13.1x
Sat, 15 Jun 2024DKK 5.0tDKK 355.3bDKK 106.2b35.5x46.7x14x
Mon, 13 May 2024DKK 4.5tDKK 354.9bDKK 106.0b34.6x42.5x12.7x
Wed, 10 Apr 2024DKK 4.4tDKK 341.2bDKK 99.6b37.3x44.2x12.9x
Fri, 08 Mar 2024DKK 4.7tDKK 341.1bDKK 99.6b38.9x47.3x13.8x
Sun, 04 Feb 2024DKK 4.0tDKK 338.6bDKK 98.5b32.7x40.6x11.8x
Tue, 02 Jan 2024DKK 3.6tDKK 320.4bDKK 90.0b32.8x40.4x11.3x
Thu, 30 Nov 2023DKK 3.6tDKK 320.5bDKK 90.0b33x39.9x11.2x
Sat, 28 Oct 2023DKK 3.4tDKK 305.6bDKK 82.3b26.6x41.5x11.2x
Mon, 25 Sep 2023DKK 3.4tDKK 305.5bDKK 82.2b33.8x41.3x11.1x
Wed, 23 Aug 2023DKK 3.4tDKK 303.7bDKK 81.3b38.4x41.4x11.1x
Fri, 21 Jul 2023DKK 3.0tDKK 287.0bDKK 75.4b40.5x39.9x10.5x
Sun, 18 Jun 2023DKK 3.0tDKK 287.1bDKK 75.5b40.5x40.3x10.6x
Tue, 16 May 2023DKK 3.2tDKK 284.8bDKK 74.9b42.4x42.7x11.2x
Thu, 13 Apr 2023DKK 3.0tDKK 272.6bDKK 68.5b42.2x44.4x11.2x
Price to Earnings Ratio

44.4x


Total Market Cap: DKK 3.0tTotal Earnings: DKK 68.5bTotal Revenue: DKK 272.6bTotal Market Cap vs Earnings and Revenue0%0%0%
Danish Healthcare Sector Price to Earnings3Y Average 31.7x202420252026
Current Industry PE
  • Investors are pessimistic on the Danish Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 11.3x which is lower than its 3-year average PE of 31.7x.
  • The 3-year average PS ratio of 9.0x is higher than the industry's current PS ratio of 3.3x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have grown 24% per year over the last three years.
  • Revenues for these companies have grown 18% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Danish Healthcare sector?

DK Market4.17%
Healthcare3.69%
Healthtech7.72%
Life Sciences4.37%
Biotech4.14%
Pharma3.66%
Medical Equipment3.45%
Healthcare Services-1.22%
Industry PE
  • Investors are most optimistic about the Healthcare Services industry which is trading above its 3-year average PE ratio of 521x.
    • Analysts are expecting annual earnings growth of 85.3%, which is higher than its past year's earnings decline of 99.7% per year.
Forecasted Growth
  • Analysts are most optimistic on the Healthcare Services industry, expecting annual earnings growth of 85% over the next 5 years.
  • This is better than its past earnings decline of 100% per year.
  • In contrast, the Life Sciences industry is expected to see its earnings decline by 8.9% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
NOVO B Novo NordiskDKK 236.902.5%
+DKK 25.5b		-45.4%PE10.3x
GMAB GenmabDKK 1.76k4.1%
+DKK 4.3b		42.5%PE17.3x
DEMANT DemantDKK 195.604.7%
+DKK 1.8b		-10.6%PE17.4x
COLO B ColoplastDKK 442.801.5%
+DKK 1.5b		-34.9%PE25x
HLUN B H. LundbeckDKK 40.783.8%
+DKK 1.5b		38.2%PE12.7x

Latest News

NOVO B
DKK 236.90
Novo Nordisk
7D
2.5%
1Y
-45.4%

NOVO B: Future Returns Will Rely On Weekly Diabetes And Obesity Treatments

Narrative Update: Novo Nordisk Price Target Shift The analyst price target for Novo Nordisk has been adjusted slightly higher to DKK 309.77 from DKK 309.63. This reflects updated analyst assumptions that incorporate revised revenue growth, profit margin and future P/E inputs.
ALK B
DKK 205.80
ALK-Abelló
7D
2.4%
1Y
50.1%
GMAB
DKK 1,758.50
Genmab
7D
4.1%
1Y
42.5%

GMAB: 2026 Late Stage Oncology Catalysts Will Support Stronger Margin Profile

Genmab's updated analyst price target now sits at DKK 3,017, a modest reset from DKK 3,060 as analysts factor in higher discount rates, revised long term margin expectations, and recent research that reflects both increased revenue growth assumptions and a lower future P/E multiple. Analyst Commentary Recent Street research around Genmab has centered on how new clinical and portfolio developments filter into valuation, with several bullish analysts updating price targets and investment cases to reflect revised expectations on execution and long term growth potential.
VIRO
DKK 11.20
ViroGates
7D
-2.2%
1Y
62.8%
GUBRA
DKK 364.20
Gubra
7D
-0.7%
1Y
1.2%

GUBRA: Obesity Trial And Ventures Expansion Will Drive Future Upside Potential

Analysts have kept their DKK price target for Gubra unchanged at DKK469.50, citing essentially stable assumptions on discount rate, revenue trajectory, profit margin and forward P/E as reasons to maintain their prior valuation view. What's in the News Clinical trial application submitted in Germany for GUB-UCN2, a first in human Phase 1/2a study targeting high quality weight loss, with about 188 participants across multiple indications and patient groups, including combination use with incretin based therapy for obesity (Product Related Announcement).
ZEAL
DKK 298.00
Zealand Pharma
7D
1.4%
1Y
-27.4%
COLO B
DKK 442.80
Coloplast
7D
1.5%
1Y
-34.9%

COLO B: New CEO Appointment And Reset P/E Will Support Future Re Rating

Coloplast's analyst fair value target has been trimmed from DKK 579.78 to DKK 567.16, as analysts factor in slightly lower long term growth, modestly softer margin assumptions and small adjustments to future P/E expectations following a mix of recent target cuts and one upgrade. Analyst Commentary Recent research on Coloplast has been mixed, with several target cuts alongside one upgrade.
PEG
DKK 0.087
Pharma Equity Group
7D
-2.7%
1Y
-21.3%
DEMANT
DKK 195.60
Demant
7D
4.7%
1Y
-10.6%

DEMANT: Recent Upgrades And 2026 Guidance May Support Further Upside

Analysts have trimmed the fair value estimate for Demant slightly to DKK 231.61 from DKK 232.17, reflecting a modest recalibration of price targets after a mix of recent upgrades and target reductions across the Street. Analyst Commentary Recent research on Demant has been mixed, with both upgrades and target cuts contributing to the slightly lower blended fair value estimate.
AMBU B
DKK 69.05
Ambu
7D
1.9%
1Y
-39.7%

AMBU B: Lower P/E Assumptions Will Support Upside If Execution Improves

Analysts have lowered their price target on Ambu by DKK 12 to reflect slightly adjusted assumptions on fair value, discount rate, revenue growth, profit margin, and future P/E following the recent JPMorgan target cut to DKK 12. Analyst Commentary Bullish Takeaways Bullish analysts see the revised fair value and discount rate assumptions as a reset that could leave room for upside if Ambu delivers on its operational targets.
HLUN B
DKK 40.78
H. Lundbeck
7D
3.8%
1Y
38.2%

HLUN B: Neurology Pipeline Progress Will Support Future Margin Expansion

Analysts have reduced their price target on H. Lundbeck to DKK 61.99 from DKK 66.52, reflecting updated assumptions for slightly softer revenue growth, profit margins, and a lower future P/E multiple.
SMSMED
DKK 3.23
Scandinavian Medical Solutions
7D
-1.2%
1Y
-25.1%

Sentiment Still Eluding Scandinavian Medical Solutions A/S (CPH:SMSMED)

Jan 27
Sentiment Still Eluding Scandinavian Medical Solutions A/S (CPH:SMSMED)